NGS-Based Proteomics Services Market

The growth of this market is mainly driven by the ability of next-generation sequencing (NGS) readouts to measure thousands of proteins in large numbers of samples at low sample volumes, the rapid growth of population-scale proteomics studies and biobank programs, the increasing use of high-plex proteomics in drug discovery and clinical development, and the integration of proteomic and genomic data in multiomics research. In addition, the expansion of biomarker research in neurology, oncology, inflammation, and cardiometabolic disease, together with the consolidation of the market around large life science tools companies with global service networks, is further supporting the growth of this market.

The NGS-Based Proteomics Services Market, also referred to as the sequencing-based proteomics services market, NGS-readout proteomics services market, or high-plex affinity proteomics services market, comprises the contract assay, data generation, and bioinformatics services that use next-generation sequencing to read out protein measurements. In these technologies, affinity reagents such as antibody pairs, aptamers, or oligonucleotide-conjugated antibodies bind target proteins, and the binding events are converted into DNA barcodes that are quantified by sequencing. The market includes services based on proximity extension assays, aptamer-based assays with an NGS readout, nucleic acid-linked immuno-sandwich assays (NULISA), and antibody-oligonucleotide conjugate methods used for single-cell and spatial proteogenomics. Services include study design, sample processing and assay services, sequencing, quality control, and data analysis and bioinformatics, delivered by platform providers, genomics and contract research service providers, and academic core facilities. Purchases of instruments and kits for in-house use are excluded.

The market is experiencing strong growth as researchers seek to measure the proteome at a scale comparable to genomics. Proteins are the direct targets of most drugs and the most immediate indicators of disease activity, but traditional immunoassays measure only a few proteins at a time, and mass spectrometry can be difficult to scale to tens of thousands of plasma samples. NGS-based proteomics overcomes these limitations by combining highly multiplexed affinity reagents with the throughput and falling cost of sequencing, enabling thousands of proteins to be measured in microliters of plasma across very large sample cohorts. This capability is making high-plex proteomics a routine component of population health studies, drug development programs, and translational research.

Population-scale studies are an important source of demand. In January 2025, UK Biobank selected the Olink Explore platform of Thermo Fisher Scientific for the UK Biobank Pharma Proteomics Project, a collaboration with 14 biopharmaceutical companies that is measuring more than 5,400 proteins in up to 600,000 samples, with staggered data releases to approved researchers beginning in 2026 and the full dataset expected in 2027. A 2023 pilot on the same platform analyzed more than 54,000 UK Biobank samples, and its findings, published in Nature, have been cited more than 400 times, demonstrating the value of combining proteomic and genetic data to identify drug targets and disease mechanisms. Illumina Protein Prep, built on SOMAmer reagents with an NGS readout, measures up to 9,500 unique human protein targets in a single experiment, and has been used by Genomics England to profile more than 7,800 rare disease participants, while UK Biobank, GSK, Johnson & Johnson, Novartis, and Standard BioTools are analyzing about 50,000 additional samples. Projects of this scale generate large volumes of contract assay and data analysis work for service providers and create reference datasets that encourage further proteomic studies.

The competitive landscape has consolidated rapidly around large life science tools companies. Thermo Fisher Scientific acquired Olink in July 2024, adding proximity extension assay technology and the Olink analysis service to its portfolio. In January 2026, Illumina completed the acquisition of SomaLogic from Standard BioTools for USD 350 million in cash at closing, plus up to USD 75 million in near-term milestones and performance-based royalties, combining the SomaScan aptamer-based assay with the Illumina NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics. Meanwhile, Alamar Biosciences is expanding quickly with its NULISA technology, which uses an NGS readout in its NULISAseq panels. Alamar Biosciences, which completed its initial public offering in April 2026 with gross proceeds of USD 219.9 million, reported Q2 2026 revenue of USD 29.4 million, up 82% year over year, with services and other revenue up 49% to USD 6.2 million, and guided to FY2026 revenue of USD 116 million to USD 120 million. In Q2 2026, Alamar launched the NULISAseq Immune 340 Panel and a multiplexed blood-based immunoassay for eMTBR-tau in its NULISAseq Neuro 220 Panel, and NULISA data were featured in more than 140 presentations at the Alzheimer Association International Conference (AAIC) 2026.

Genomics and contract research service providers are also expanding their NGS-based proteomics offerings. Novogene offers Olink Explore HT services across its global laboratories, and Azenta Life Sciences offers Olink and Alamar NULISA proteomics services through GENEWIZ. Academic core facilities, such as the National Genomics Infrastructure in Sweden, provide proteomics services with an NGS readout to research groups. These providers allow pharmaceutical companies, academic institutions, and biobanks to access high-plex proteomics without investing in specialized equipment and expertise.

Demand for these services spans a wide range of applications. Pharmaceutical and biotechnology companies use high-plex proteomics to identify and validate drug targets, understand mechanisms of action, and measure pharmacodynamic responses and safety signals in clinical trial samples. Biobanks and population health programs add proteomic data to genomic and health record data to study disease risk and progression, while academic researchers use these services to discover biomarkers in neurology, oncology, inflammation and immunology, and cardiometabolic disease. Because NGS-based proteomics requires only small volumes of plasma or serum, it is particularly well suited to stored biobank and clinical trial samples, allowing researchers to generate new data from existing sample collections.

At the same time, the market faces important structural changes. The introduction of kits designed for laboratories with existing sequencers, such as Olink Reveal and Illumina Protein Prep, allows some customers to bring proteomics in-house, while the integration of proteomic data with genomics through software such as DRAGEN and Illumina Connected Multiomics is expanding the role of data analysis services. As a result, service providers that can deliver large-scale studies, high data quality, and advanced bioinformatics are expected to capture the largest share of growth over the forecast period.